Why XRTX rose 22.1% on Oct 8 2026: planned regulatory filing
XRTX+22.1%on Thu Oct 8 2026
XORTX Therapeutics Inc. Common Stock was up 22.1% on the day at $2.13, ranked #2 on 164× its usual five-minute volume, when TapeRank recorded this spike at 16:08 ET during after hours. TapeRank recorded 2 events for XRTX that day, between 16:03 and 16:08 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 16:03 ETUNEXPLAINED MOVE · AFTER-HOURS
$2.01 · ▲ 15.1% ON THE DAY · 33.8× 5M RVOL · RANK #1
UNEXPLAINEDNO FILINGS · RULEXRTX is up 10.0% on the day on 22.5x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 16:01 ET · 2 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 16:03 ET
LAST2.01DAY▲ 15.1%5 MIN▲ 10.35%5M RVOL33.8×5M $VOL$245KFLOAT*1.8MRANK#1SESSIONAFTER-HOURSVWAP1.93HOD2.09LOD1.72OR HIGH—OR LOW—PREV CLOSE1.75PM HIGH1.73PM LOW1.73GAP▲ 0.29%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 16:08 ETMOVER · AFTER-HOURS
$2.13 · ▲ 22.1% ON THE DAY · 164× 5M RVOL · RANK #2
STRETCHEDCONFIDENCE4/5XRTX rose 14.0% on the day and another 3.11% in five minutes after announcing plans for a Health Canada clinical trial application for XORLO ahead of a planned FDA filing. The regulatory plans are a concrete but forward-looking milestone without disclosed approval, trial, or financial outcomes, making the move outsized relative to the news.
WHYUp 14.0% on a planned clinical-trial application and planned FDA filing, with no approval or quantified outcome, is a larger move than the catalyst supports.ANALYZED 16:06 ET · 2 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 16:08 ET
LAST2.13DAY▲ 22.1%5 MIN▲ 8.12%5M RVOL164×5M $VOL$1.1MFLOAT*1.8MRANK#2SESSIONAFTER-HOURSVWAP2.02HOD2.14LOD1.72OR HIGH—OR LOW—PREV CLOSE1.75PM HIGH1.73PM LOW1.73GAP▲ 0.29%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:36 ETOpened at $1.75, +0.3% on the previous close of $1.75
- 11:41 ETRegular-session low, $1.72
- 13:08 ETRegular-session high, $1.82
- 15:54 ETLast trade of the regular session, $1.81, +3.7% on the previous close of $1.75
- Volume: 14K shares in regular hours, 827 before the open
XRTX opened at $1.75, slipped to a session low of $1.72, then recovered to $1.82 before ending regular trading at $1.81. TapeRank later recorded an unexplained move to $2.01 at 16:03 ET and $2.13 at 16:08 ET, with no halts; its read tied the rise to XORTX’s plan to submit a Health Canada clinical trial application for gout drug XORLO ahead of a planned FDA filing, while noting that the forward-looking regulatory milestone disclosed no approval, trial, or financial outcome.
WRITTEN THU OCT 15 2026 18:03 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list